ZELBORAF Patient Assistance Program
Don’t let the high cost of brand specialty BRAF-targeted therapy stand between you and the treatment you need. We help eligible patients access Zelboraf (vemurafenib) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing — Applying To Genentech Directly Is Always Free
- Paperwork, Documentation & Oncology-Practice Coordination Handled For You
- Comprehensive Support: From Application to Entire Journey.
- BRAF-Testing Documentation Support — The Prerequisite Insurers Check First
- Combination-Therapy Coordination — Zelboraf Rarely Travels Alone
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Zelboraf (Vemurafenib) Is A BRAF Kinase Inhibitor For Metastatic Melanoma With BRAF V600E Mutations — And For The Rare Disease Erdheim-Chester — Prescribed Only After An FDA-Approved Test Confirms The Mutation, Usually Today In Combination With Cobimetinib.
- The Cost Is Serious: Eight 240 mg Tablets Daily Puts Cash Prices Near $12,000 Per Month — Roughly $150,000 Per Year — With No Generic, Though Vemurafenib’s First Patents Expire Across 2026, Putting Generic Entry On The Horizon For The First Time.
- The Genentech Patient Foundation Provides Free Medicine To Uninsured Patients With Household Income Under $150,000 — One Of The Most Generous Thresholds In All Of Pharma — And To Insured Patients With Coverage Gaps Who Meet Income Requirements.
- Commercially Insured Patients Get Up To $25,000 Per Year Through The Genentech Oncology Co-pay Program, And Medicare Patients Get The $2,100 Part D Cap (2026) — A Hard Ceiling Worth More Than Any Card On A $150,000 Drug.
What Is Zelboraf Prescription Assistance Program?
The Zelboraf Patient Assistance Program is run by the Genentech Patient Foundation (1-888-941-3331, Mon–Fri 6 AM–5 PM PT), which provides free Genentech medicine to uninsured patients with household income under $150,000 a year (add $25,000 per household member beyond four) and to insured patients with coverage gaps who meet income requirements after other assistance is tried. Alongside it: the Genentech Oncology Co-pay Assistance Program (1-855-692-6729) covers commercially insured patients up to $25,000 per calendar year, and for Medicare patients the $2,100 Part D cap plus the monthly payment plan bounds even a $150,000 drug. Zelboraf adds two structural wrinkles: BRAF V600 testing documentation is the gate every insurer checks first, and modern practice usually pairs vemurafenib with cobimetinib (Cotellic) — a second specialty drug with its own programs, doubling the paperwork exactly when families have the least bandwidth for it. For a flat $69.95 per month, our Patient Advocates manage both drugs’ programs, the testing file, and every renewal through treatment.
Pharmacy Price Comparison
- Without assistance, Aimovig costs hundreds of dollars per month at retail pharmacies. Discount programs offer some relief, but they don’t come close to what a Patient Assistance Program provides if you qualify.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$299 | Save ~$229/mo |
| CVS Pharmacy | ~$299 | Save ~$229/mo |
| Walmart | ~$299 | Save ~$229/mo |
| Costco | ~$310 | Save ~$240/mo |
| SingleCare (140mg) | ~$768 | Save ~$698/mo |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026.*
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Zelboraf Prescription Program?
The Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management. Our $69.95/month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through Afford My Prescriptions is the better long–term solution:
Limitations of Coupons
- Prices fluctuate — savings aren’t guaranteed month-to-month
- Copay accumulators may prevent savings from counting toward deductible
- Cards expire and require constant renewal
- Subject to strict monthly or annual maximum savings caps
- Can’t be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly from the manufacturer
- We manage all paperwork, refills, and renewals
- If denied, we explore alternative savings on your behalf
DO YOU QUALIFY?
The Genentech Patient Foundation publishes clear eligibility rules. You will generally qualify if the following are true — and if your situation doesn’t fit neatly, contact AffordMyPrescriptions so we can review your case and determine if you qualify for Zelboraf assistance:
- You are a U.S. citizen or legal resident
- You Have A Valid Zelboraf Prescription With Documented BRAF V600 Mutation Testing
- You Are Uninsured — Or Insured With Coverage Gaps After Other Assistance Is Tried
- You have Medicare Part D and are struggling with out-of-pocket drug costs (the program accepts Medicare patients)
- You have recently experienced a change in financial circumstances That Affects Your Ability to Pay
- Your Household Income Is Under $150,000 (Plus $25,000 Per Household Member Beyond Four)
Understanding Aimovig:
Zelboraf (vemurafenib) is a BRAF kinase inhibitor — one of the first precision cancer medicines, built to shut down the specific mutated growth switch (BRAF V600E) that drives about half of metastatic melanomas.
How Zelboraf Works:
In BRAF-mutant melanoma, a single amino-acid change jams a growth-signaling kinase permanently on. Vemurafenib binds that mutant kinase selectively and silences it — often shrinking tumors within weeks. The mutation requirement is absolute: the label mandates an FDA-approved test, and in wild-type BRAF the drug can paradoxically stimulate growth. Modern practice usually adds cobimetinib, a MEK inhibitor one step downstream, because blocking the pathway at two points deepens responses and delays resistance.
Form and Use:
Four 240 mg tablets twice daily — eight tablets, every day — through specialty pharmacy distribution. That pill burden is also the price burden: at roughly $53 per tablet, each day costs over $400 at list. Treatment continues until progression or intolerance, with dose reductions available; combination use adds cobimetinib’s own calendar and costs, which is why the two programs need managing as one.
Generic Availability:
None yet — but the horizon finally moved: vemurafenib’s first patents expire across 2026, with later patents running to 2032. No generic is approved as of now, and limited-distribution specialty drugs genericize slowly, so plan around the programs — while we watch the filings.
Warnings:
Vemurafenib’s signature risk is new skin cancers — cutaneous squamous cell carcinomas develop in a meaningful fraction of patients, making scheduled dermatologic exams part of treatment, not optional extras. Severe photosensitivity demands real sun protection daily. QT prolongation, liver enzyme elevations, severe rashes, and joint pain round out the monitoring list; combination with cobimetinib adds eye and heart checks. Report new skin lesions, vision changes, or palpitations promptly.
FAQ (Frequently Asked Questions)
How Much Does Zelboraf Cost Without Insurance?
Roughly $12,000 per month at the standard eight-tablets-daily dose — about $150,000 per year, with no generic. Uninsured patients with household income under $150,000 can receive it free through the Genentech Patient Foundation; our $69.95 monthly fee covers full advocacy across both combination drugs.
Does The $150,000 Income Limit Really Mean What It Says?
Yes — the Genentech Patient Foundation’s uninsured threshold is household income under $150,000 (plus $25,000 per member beyond four), among the most generous in the industry. Families who assume they earn too much for assistance routinely qualify here. Insured patients with gaps have a separate income-tested path.
Does Medicare Cover Zelboraf?
Yes — under Part D as a self-administered oral, where the $2,100 annual cap (2026) is the decisive protection and the payment plan spreads it monthly. The copay card excludes Medicare, but on a capped benefit the math already works; Extra Help applies for low incomes.
What About Cotellic — Doesn’t It Double The Cost?
Combination therapy means two specialty drugs, two programs, two renewals — but Genentech’s foundation and copay programs cover Cotellic too, and we run both in parallel so the combination never costs more than the worse of the two coverages. Ask us to map the pair before treatment starts.
Is A Generic Coming?
The first vemurafenib patents expire across 2026, so filings are finally possible — but nothing is approved, and specialty oncology generics arrive slowly. Plan on the programs; we monitor the horizon.
Why All The Skin Checks During Treatment?
BRAF inhibitors can trigger new squamous cell skin cancers — usually caught early and removed simply, which is exactly why scheduled dermatology visits are built into treatment. Photosensitivity is also severe; daily sun protection isn’t advice, it’s part of the regimen.
What if my application is denied?
Denials are usually about documentation — income proof, the BRAF test report, or the “other assistance tried” record insured applicants need. Applications can be corrected and resubmitted, and we treat oncology resubmissions as urgent by default. We review the denial letter, fix what triggered it, and resubmit on your behalf.
Take Control of Your Medication Costs
A $150,000 drug with a $150,000 income threshold on its free-medicine program — Zelboraf’s affordability gap is narrower than almost anyone assumes, once the paperwork is done right, twice, for both halves of combination therapy. That’s our job. Check your eligibility today; the pre-qualification review is free, and if we can’t help you, you pay nothing.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.